Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Active, not recruiting · NCT01841723 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hairy cell leukemia variant, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT01841723 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | United States | 687 |
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| UT MD Anderson Cancer Center | Houston | United States | 204 |
| Wayne State University/Karmanos Cancer Institute | Detroit | United States | 196 |